Nerandomilast has demonstrated significant potential in reducing lung inflammation and fibrosis in experimental models of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD). This autoimmune condition, marked by progressive lung damage, currently has limited treatment options.
Researchers explored nerandomilast, a phosphodiesterase 4B inhibitor, as a therapeutic agent. Studies in a preclinical mouse model of IIM-ILD showed that nerandomilast treatment led to marked improvements. Key findings included reduced muscle inflammation, pulmonary fibrosis, and overall lung inflammation.
Further analysis revealed nerandomilast's direct impact on immune cells in the lungs. The drug decreased B cell infiltration and proliferation, lowered the activation marker BAFF, and suppressed B cell differentiation into plasma cells. Serological tests also indicated a reduction in anti-Jo-1 autoantibodies, pointing to a dampening of autoimmune activity.
Mechanistically, nerandomilast was found to increase cyclic adenosine monophosphate levels in lung tissue, inhibiting critical signaling pathways like PI3K/AKT, NF-κB, and STAT3 in B cells. This suggests the drug effectively modulates immune signaling networks responsible for B cell activation and pathogenic antibody production. These findings position nerandomilast as a promising therapeutic candidate for IIM-ILD, meriting further investigation.